Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 1:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pulmonary Clear all
Withdrawn Phase 1 Interventional

CLBS119 for Repair of COVID-19 Induced Pulmonary Damage

NCT04522817
View directory record Official record
Conditions
Covid-19
Interventions
CLBS119
Biological
Lead sponsor
Lisata Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Sep 23, 2026, 1:47 PM EDT
Completed Phase 2 Interventional

Valacyclovir Plus Celecoxib for Post-Acute Sequelae of SARS-CoV-2

NCT06316843
View directory record Official record
Conditions
Long COVID, PASC Post Acute Sequelae of COVID 19
Interventions
Valacyclovir celecoxib dose 1, Valacyclovir celecoxib dose 2, Placebo
Drug
Lead sponsor
Bateman Horne Center
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 21, 2025 · Synced Sep 23, 2026, 1:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-drug Interaction Study of S-892216 Coadministered With Carbamazepime to Healthy Adult Participants

NCT06751017
View directory record Official record
Conditions
COVID-19
Interventions
S-892216, Carbamazepine
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Sep 23, 2026, 1:47 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Detection of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Activity in Rectal Tissues From Human Subjects

NCT01078740
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
CF Therapeutics Development Network Coordinating Center
Network
Eligibility
18 Years to 75 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
3
States / cities
Birmingham, Alabama • Iowa City, Iowa • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 6, 2013 · Synced Sep 23, 2026, 1:47 PM EDT
Terminated Phase 2 Interventional Results available

Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma

NCT01032850
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Sorafenib & Capecitabine
Drug
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
3
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jun 1, 2021 · Synced Sep 23, 2026, 1:47 PM EDT
Not listed No phase listed Observational

Vibroacoustic Study of Lung Development in Newborn Infants

NCT05827250
View directory record Official record
Conditions
Prematurity, Premature Birth, Premature Lungs, Prematurity; Extreme
Interventions
imPulse Tor
Device
Lead sponsor
Level 42 AI, Inc.
Industry
Eligibility
0 Years to 2 Years
Enrollment
200 participants
Timeline
2023 – 2025
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 24, 2023 · Synced Sep 23, 2026, 1:47 PM EDT
Completed Phase 4 Interventional

Longitudinal Cohort Study in Participants With Severe Asthma to Assess Biomarkers

NCT02537691
View directory record Official record
Conditions
Asthma
Interventions
FP, LABA, LTRA, LAMA, Theophylline, Oral Corticosteroids
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
483 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
29
States / cities
Birmingham, Alabama • Mission Viejo, California • Sacramento, California + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2019 · Synced Sep 23, 2026, 1:47 PM EDT
Completed Not applicable Interventional Results available

Duration of Continuous Positive Airway Pressure and Pulmonary Function Testing in Preterm Infants

NCT02249143
View directory record Official record
Conditions
Respiratory Distress Syndrome, Bronchopulmonary Dysplasia
Interventions
CPAP and room air
Device
Lead sponsor
Oregon Health and Science University
Other
Eligibility
Up to 1 Year
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Sep 23, 2026, 1:47 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Prospective Study of Dietary Factors, BMI, and Risk of Asthma in Children

NCT00454415
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
9 Years to 14 Years
Enrollment
16,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 26, 2012 · Synced Sep 23, 2026, 1:47 PM EDT
Completed Phase 3 Interventional Results available

Adaptive COVID-19 Treatment Trial 4 (ACTT-4)

NCT04640168
View directory record Official record
Conditions
COVID-19
Interventions
Baricitinib, Dexamethasone, Placebo, Remdesivir
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
1,010 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
61
States / cities
Birmingham, Alabama • Fresno, California • La Jolla, California + 50 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2022 · Synced Sep 23, 2026, 1:47 PM EDT
Completed Phase 2 Interventional Results available

BATTLE Program: ZD6474 in Previously Treated Subjects With NSCLC

NCT00410189
View directory record Official record
Conditions
Lung Cancer
Interventions
ZD6474
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 22, 2015 · Synced Sep 23, 2026, 1:47 PM EDT
Recruiting Phase 1Phase 2 Interventional

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

NCT04585750
View directory record Official record
Conditions
Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor, Lung Cancer, Ovarian Cancer, Endometrial Cancer, Prostate Cancer, Colorectal Cancer, Breast Cancer, Other Cancer, Locally Advanced, Head and Neck Cancer, Gall Bladder Cancer, Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Small Cell Lung Carcinoma, NSCLC, NSCLC (Non-small Cell Lung Cancer), SCLC, Non-Small Cell Lung Carcinoma, Triple Negative Breast Cancer, TNBC, HER2+ Breast Cancer, Non-Small Cell Lung Cancer, ER/PR Positive Breast Cancer, HER2- Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, ER/PR(+), Her2(-) Breast Cancer
Interventions
rezatapopt, pembrolizumab
Drug
Lead sponsor
PMV Pharmaceuticals, Inc
Industry
Eligibility
12 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
33
States / cities
Irvine, California • La Jolla, California • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 23, 2026, 1:47 PM EDT
Terminated Phase 1 Interventional

A Study to Investigate LYL845 in Adults With Solid Tumors

NCT05573035
View directory record Official record
Conditions
Melanoma, Non-small Cell Lung Cancer, Colorectal Cancer
Interventions
LYL845
Biological
Lead sponsor
Lyell Immunopharma, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
18
States / cities
Sacramento, California • Santa Monica, California • Stanford, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2025 · Synced Sep 23, 2026, 1:47 PM EDT
Completed Phase 4 Interventional Results available

PTC Study to Evaluate Ataluren in Combination With Ivacaftor

NCT03256968
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ataluren
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
6 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 25, 2020 · Synced Sep 23, 2026, 1:47 PM EDT
Recruiting Not applicable Interventional

Dental Cleaning to Prevent Chronic Graft-Versus-Host Disease

NCT07535008
View directory record Official record
Conditions
Chronic Graft Versus Host Disease, Acute Graft Versus Host Disease, Hematopoietic and Lymphatic System Neoplasm
Interventions
Dental Cleaning, Dental Plaque sampling
Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 23, 2026, 1:47 PM EDT
Completed No phase listed Observational

Novel Index (PIMR) in PAH

NCT05812976
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Pulmonary Index of Microcirculatory Resistance, Right Ventricle Index of Microcirculatory Resistance
Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced Sep 23, 2026, 1:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase 1 Study on Bioavailability, Food Effect, and Drug-Drug Interaction of ALG-097558 Tablets in Healthy Volunteers

NCT06945276
View directory record Official record
Conditions
COVID-19
Interventions
ALG-097558, Dabigatran, Itraconazole, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Sep 23, 2026, 1:47 PM EDT
Completed Phase 2 Interventional Results available

Cisplatin, Etoposide, and Bevacizumab in Treating Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer

NCT00079040
View directory record Official record
Conditions
Extensive Stage Small Cell Lung Cancer
Interventions
cisplatin, etoposide, bevacizumab, laboratory biomarker analysis
Drug · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 13, 2014 · Synced Sep 23, 2026, 1:47 PM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Hydroxychloroquine as Prophylaxis for COVID-19 in Healthcare Workers (HCQPreP)

NCT04363450
View directory record Official record
Conditions
COVID-19, Corona Virus Infection, Wuhan Coronavirus, Prophylaxis, Healthcare Worker, Sars-CoV2, Hydroxychloroquine
Interventions
Hydroxychloroquine, Placebo
Drug
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
18 Years and older
Enrollment
1,700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Lafayette, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 1, 2020 · Synced Sep 23, 2026, 1:47 PM EDT
Completed Phase 1 Interventional

Comparative Effects of Fish Oil Supplementation and a Montelukast on EIB and Airway Inflammation in Asthma

NCT00676468
View directory record Official record
Conditions
Asthma
Interventions
Active Montelukast + Fish Oil Placebo, Active Fish Oil + Montelukast Placebo, Active Montelukast + Active Fish Oil
Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 40 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Bloomington, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 8, 2009 · Synced Sep 23, 2026, 1:47 PM EDT
Enrolling by invitation Phase 2 Interventional

DMSO Dual-Route Therapy for Refractory Tinnitus in Long-COVID and Post-COVID-19 Vaccine Injury

NCT07567274
View directory record Official record
Conditions
Tinnitus
Interventions
DMSO-based otic solution with betahistine, dexamethasone, and lidocaine, DMSO-based transdermal cream with levocarnitine and N-acetylcysteine
Drug
Lead sponsor
Leading Edge Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Ithaca, New York
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Sep 23, 2026, 1:47 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)

NCT06616974
View directory record Official record
Conditions
Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
Interventions
TX000045- Dose A, TX000045- Dose B, Placebo
Drug
Lead sponsor
Tectonic Therapeutic
Industry
Eligibility
18 Years to 83 Years
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
25
States / cities
Phoenix, Arizona • Scottsdale, Arizona • San Francisco, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 23, 2026, 1:47 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Montelukast for Early Life Wheezing

NCT00115297
View directory record Official record
Conditions
Lung Diseases, Asthma
Interventions
Montelukast, Placebo
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
3 Months to 3 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2016
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Sep 23, 2026, 1:47 PM EDT
Recruiting Phase 1 Interventional

Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma

NCT06885697
View directory record Official record
Conditions
Mesothelioma, Neoplasms, Stomach Neoplasms, Pancreatic Neoplasms, Ovarian Neoplasms, Lung Neoplasms, Thymus Neoplasms, Colonic Neoplasms
Interventions
cyclophosphamide, fludarabine, TNhYP218 CAR T Cells, mesothelin expression testing
Drug · Biological · Device
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2044
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 23, 2026, 1:47 PM EDT